Overview
Status
Active
Registry date
2019-01-07
Share capital
400,000.00 PLN
Registered address
ul. Zajęcza 15, 00-351 Warszawa, Poland
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2024 – the filing deadline has passed.
- 2024not filed
- 202321/05/2024
- 202224/05/2023
- 202129/06/2022
- 202020/05/2021
- 201915/06/2020
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2023.
Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations245 / 330
Top 74%
Voivodeship · Mazowieckie91,101 / 142,033
Top 64%
Country · Poland327,994 / 495,860
Top 66%
Results vs industry
Revenue
This companyUSD 51.08kMedianUSD 165.97kAverageUSD 2.30m
Net profit
This companyUSD -609.55kMedianUSD 1.32kAverageUSD 109.80k
Operating costs
This companyUSD 473.50kMedianUSD 201.81kAverageUSD 2.10m
Assets
This companyUSD 185.41kMedianUSD 118.27kAverageUSD 1.54m
Industry
Authorized Representatives
Piotr Igor Błaszczyk – Vice President of the Management Board
Feng Rongli – Management Board Member
Wu Yifang – President of the Management Board
Manner of representation
The declarations of will and signing on behalf of the company may be made by two members of the management board acting jointly or by a member of the management board acting jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Tridem Pharma Sas [ S.A. Uproszczona Prawa Francuskiego] | 1,000 | $108,049.70 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2019-02-01.
91 1030 1508 0000 0008 1910 3000
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Natur DayS.A. | $680,635.59 | naturday.pl | ||
| Biotriosp. z o.o. | $453,662.22 | biotrio.pl | ||
| Nature's Voicesp. z o.o. | $181,977.76 | naturesvoice.eu | ||
| Pexon Polandsp. z o.o. | $122,615.96 | pexon.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Bioresearch PharmaS.A. | $21,432.15 | bioresearchpharma.com | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Grupa FinepharmS.A. | – | finepharm.pl |
FAQ
The main business activity of Fosun Pharma focuses on manufacture of basic pharmaceutical products.
The company was registered in the Polish National Court Register (KRS) on January 7, 2019.
The headquarters is located at: ul. Zajęcza 15, 00-351 Warszawa.
The share capital of the company is PLN 400,000 (approx. $108,050).
The latest available financial statement covers the period from January 1, 2023 to December 31, 2023.
In 2023, the company generated total revenue of $51,078, representing a decrease of 13.7% compared to 2022.
No, in 2023 the company was not profitable, reporting a net loss of $609,551. For comparison, in 2022 the loss was $502,775, meaning the company increased its loss by 14.3%.
The largest operating cost category falls under employee remuneration. This category amounted to $270,944 in 2023, representing 57% of all operating expenses.
Last updated: 2026-10-07